9II9

Crystal structure of SARS-CoV-2 neutralizing antibody K4-66

Summary for 9II9

• Entry DOI: 10.2210/pdb9ii9/pdb
• Descriptor: antigen-binding fragments (Fabs) (2 entities in total)
• Functional Keywords: antigen-binding fragments (fabs), immune system
• Biological source: Homo sapiens; More
• Total number of polymer chains: 4
• Total formula weight: 93043.53

Authors

Kimura, T.K.,Hashiguchi, T. (deposition date: 2024-06-19, release date: 2024-11-06, Last modification date: 2024-11-13)

Primary citation

Kuwata, T.,Kaku, Y.,Biswas, S.,Matsumoto, K.,Shimizu, M.,Kawanami, Y.,Uraki, R.,Okazaki, K.,Minami, R.,Nagasaki, Y.,Nagashima, M.,Yoshida, I.,Sadamasu, K.,Yoshimura, K.,Ito, M.,Kiso, M.,Yamayoshi, S.,Imai, M.,Ikeda, T.,Sato, K.,Toyoda, M.,Ueno, T.,Inoue, T.,Tanaka, Y.,Kimura, K.T.,Hashiguchi, T.,Sugita, Y.,Noda, T.,Morioka, H.,Kawaoka, Y.,Matsushita, S.
Induction of IGHV3-53 public antibodies with broadly neutralising activity against SARS-CoV-2 including Omicron subvariants in a Delta breakthrough infection case.
Ebiomedicine, 110:105439-105439, 2024

PubMed Abstract: Emergence of SARS-CoV-2 variants that escape neutralising antibodies hampers the development of vaccines and therapeutic antibodies against SARS-CoV-2. IGHV3-53/3-66-derived public antibodies, which are generally specific to the prototype virus and are frequently induced in infected or vaccinated individuals, show minimal affinity maturation and high potency against prototype SARS-CoV-2.

PubMed: 39488016
DOI: 10.1016/j.ebiom.2024.105439

Experimental method

X-RAY DIFFRACTION (2.9 Å)